This month's top tech news stories
BIOHIT HealthCare
Atrophic gastritis
A clinical validation study has confirmed the high accuracy of BIOHIT Oyj’s new-generation GastroPanel test for the diagnosis of atrophic gastritis (AG) and Helicobacter pylori (Hp) infection in patients referred for gastroscopy.
The test is designed for the first-line diagnosis of Hp infection and AG in patients with upper abdominal symptoms, such as dyspepsia and gastro-oesophageal reflux disease, before endoscopy.
Bruker
Diagnostics
Université de Paris has installed a Bruker In Vitro Diagnostic research (IVDr) nuclear magnetic resonance (NMR) spectrometer within its MetaboParis-Santé platform. One of the most prestigious universities in France, known for its cutting-edge research in medicine and more broadly biology and health, is the first facility in the country to benefit from an IVDr instrument of this kind. MetaboParis-Santé is upheld as a national centre of excellence for metabolic analysis by NMR of human biofluids.
Cancer drug
CellCentric, a clinical-stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, has received funding from BrightEdge, the impact venture capital fund of the American Cancer Society.
The funding will be used to further progress the clinical development of its ground-breaking, targeted treatment, inobrodib (formerly known as CCS1477). Inobrodib is a first-in-class small molecule inhibitor that impacts twin regulatory proteins p300 and CBP and affects a number of established, yet elusive-to-treat oncogenes.
